[1] Messina JP, Humphreys I, Flaxman A, et al. Global distribution and prevalence of hepatitis C virus genotypes[J]. Hepatology,2015,61(1):77-87.
[2] Sarrazin C. Treatment failure with DAA therapy: Importance of resistance[J]. J Hepatol,2021,74(6):1472-1482.
[3] Polaris Observatory HCV Collaborators. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study[J]. Lancet Gastroenterol Hepatol, 2022,7(5):396-415.
[4] Gottwein JM, Scheel TK, Callendret B, et al. Novel infectious cDNA clones of hepatitis C virus genotype 3a (strain S52) and 4a (strain ED43): genetic analyses and in vivo pathogenesis studies[J]. J Virol, 2010,84(10):5277-5293.
[5] Fernandez-Antunez C, Wang K, Fahnøe U, et al. Characterization of multi-DAA resistance using a novel hepatitis C virus genotype 3a infectious culture system[J]. Hepatology,2023,78(2):621-636.
[6] Howe AYM, Rodrigo C, Cunningham EB, et al. Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals[J]. J HEP Rep,2022,4(5):100462.
[7] Dietz J, Di Maio VC, de Salazar A, et al. Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy[J]. J Hepatol,2021,74(4):801-810.
[8] Dietz J, Müllhaupt B, Buggisch P, et al. Long-term persistence of HCV resistance-associated substitutions after DAA treatment failure[J]. J Hepatol,2023,78(1):57-66.
[9] Vo-Quang E, Soulier A, Ndebi M, et al. Virological characterization of treatment failures and retreatment outcomes in patients infected with "unusual" HCV genotype 1 subtypes[J]. Hepatology, 2023,78(2):607-620.
[10] Childs K, Davis C, Cannon M, et al. Suboptimal SVR rates in African patients with atypical genotype 1 subtypes: Implications for global elimination of hepatitis C[J]. J Hepatol, 2019,71(6):1099-1105.
[11] Gupta N, Mbituyumuremyi A, Kabahizi J, et al. Treatment of chronic hepatitis C virus infection in Rwanda with ledipasvir-sofosbuvir (SHARED): a single-arm trial[J]. Lancet Gastroenterol Hepatol,2019,4(2):119-126. |
